Characterizing acyl-carnitine biosignatures for schizophrenia: a longitudinal pre- and post-treatment study
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Subjects with schizophrenia have high risks of metabolic abnormalities and bioenergetic dysfunction. Acyl-carnitines involved in bioenergetic pathways provide potential biomarker targets for identifying early changes and onset characteristics in subjects with schizophrenia. We measured 29 acyl-carnitine levels within well-characterized plasma samples of adults with schizophrenia and healthy controls using liquid chromatography-mass spectrometry (LC-MS). Subjects with schizophrenia were measured at baseline and after 8 weeks of treatment. A total of 225 subjects with schizophrenia and 175 age- and gender-matched healthy controls were enrolled and 156 subjects completed the 8-week follow-up. With respect to plasma acyl-carnitines, the individuals with schizophrenia at baseline showed significantly higher levels of C4-OH (C3-DC) and C16:1, but lower concentrations of C3, C8, C10, C10:1, C10:2, C12, C14:1-OH, C14:2, and C14:2-OH when compared with healthy controls after controlling for age, sex, body mass index (BMI), smoking, and drinking. For the comparison between pretreatment and posttreatment subjects, all detected acyl-carnitines were significantly different between the two groups. Only the concentration of C3 and C4 were increased after selection by variable importance in projection (VIP) value >1.0 and false discovery rate (FDR) q value <0.05. A panel of acyl-carnitines were selected for the ability to differentiate subjects of schizophrenia at baseline from controls, pre- from post-treatment, and posttreatment from controls. Our data implicated acyl-carnitines with abnormalities in cellular bioenergetics of schizophrenia. Therefore, acyl-carnitines can be potential targets for future investigations into their roles in the pathoetiology of schizophrenia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Systematic Review of the Prevalence of Schizophrenia
Saha, S., Chant, D., Welham, J., & McGrath, J. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020141 · Cited by 2,168
Koves, T. R., Ussher, J. R., Noland, R. C., Slentz, D., Mosedale, M., Ilkayeva, O., Bain, J., Stevens, R., Dyck, J. R. B., Newgard, C. B., et al. (2008) · Cell Metabolism · doi:10.1016/j.cmet.2007.10.013 · Cited by 1,990
Fatty acid import into mitochondria
Kerner, J., & Hoppel, C. (2000) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/s1388-1981(00)00044-5 · Cited by 937
Carnitine: a nutritional, biosynthetic, and functional perspective
STEIBER, A. (2004) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2004.06.006 · Cited by 446
Lipid-Induced Mitochondrial Stress and Insulin Action in Muscle
Muoio, D. M., & Neufer, P. D. (2012) · Cell Metabolism · doi:10.1016/j.cmet.2012.04.010 · Cited by 343
Neuroimaging-aided differential diagnosis of the depressive state
Takizawa, R., Fukuda, M., Kawasaki, S., Kasai, K., Mimura, M., Pu, S., Noda, T., Niwa, S.-I., & Okazaki, Y. (2014) · NeuroImage · doi:10.1016/j.neuroimage.2013.05.126 · Cited by 337
Noland, R. C., Koves, T. R., Seiler, S. E., Lum, H., Lust, R. M., Ilkayeva, O., Stevens, R. D., Hegardt, F. G., & Muoio, D. M. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.032888 · Cited by 317
A review of current evidence for acetyl-l-carnitine in the treatment of depression
Wang, S.-M., Han, C., Lee, S.-J., Patkar, A. A., Masand, P. S., & Pae, C.-U. (2014) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2014.02.005 · Cited by 110
Functional near-infrared spectroscopy in psychiatry
Lai, C. Y. Y., Ho, C. S. H., Lim, C. R., & Ho, R. C. M. (2017) · BJPsych Advances · doi:10.1192/apt.bp.115.015610 · Cited by 77
Cited by
Acylcarnitines: Nomenclature, Biomarkers, Therapeutic Potential, Drug Targets, and Clinical Trials
Dambrova, M., Makrecka-Kuka, M., Kuka, J., Vilskersts, R., Nordberg, D., Attwood, M. M., Smesny, S., Sen, Z. D., Guo, A. C., Oler, E., et al. (2022) · Pharmacological Reviews · doi:10.1124/pharmrev.121.000408 · Cited by 507
MahmoudianDehkordi, S., Ahmed, A. T., Bhattacharyya, S., Han, X., Baillie, R. A., Arnold, M., Skime, M. K., John-Williams, L. S., Moseley, M. A., Thompson, J. W., et al. (2021) · Translational Psychiatry · doi:10.1038/s41398-020-01097-6 · Cited by 95
Liu, Y., Song, X., Liu, X., Pu, J., Gui, S., Xu, S., Tian, L., Zhong, X., Zhao, L., Wang, H., et al. (2021) · Psychiatry and Clinical Neurosciences · doi:10.1111/pcn.13194 · Cited by 48
Lipids in Psychiatric Disorders: Functional and Potential Diagnostic Role as Blood Biomarkers
Zorkina, Y., Ushakova, V., Ochneva, A., Tsurina, A., Abramova, O., Savenkova, V., Goncharova, A., Alekseenko, I., Morozova, I., Riabinina, D., et al. (2024) · Metabolites · doi:10.3390/metabo14020080 · Cited by 36
Wang, F., Guo, L., Zhang, T., Cui, Z., Wang, J., Zhang, C., Xue, F., Zhou, C., Li, B., Tan, Q., et al. (2022) · Medicina · doi:10.3390/medicina58111509 · Cited by 18
“Likewise, AcCa also plays a key role in the pathophysiology of SCZ [37], and AcCa supplementation therapies have been used in individuals with SCZ [38].”
BackgroundSelf-citation
Metadata
- Authors
- Cao, B., Wang, D., Pan, Z., Brietzke, E., McIntyre, R. S., Musial, N., Mansur, R. B., Subramanieapillai, M., Zeng, J., Huang, N., & Wang, J.
- Venue
- Translational Psychiatry
- Published
- 2019-01-17
- Volume
- 9
- Issue
- 1
- Pages
- 19-19
- ISSN
- 2158-3188 (ISSN-L)
- OpenAlex
- W2910493805
- Cited by
- 81
- References
- 9
- FWCI
- 6.15
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Characterizing acyl-carnitine biosignatures for schizophrenia: a longitudinal pre- and post-treatment study. https://app.cochat.ai/papers/10.1038/s41398-018-0353-x
- The paper
- Cao, B., Wang, D., Pan, Z., Brietzke, E., McIntyre, R. S., Musial, N., Mansur, R. B., Subramanieapillai, M., Zeng, J., Huang, N., & Wang, J. (2019). Characterizing acyl-carnitine biosignatures for schizophrenia: a longitudinal pre- and post-treatment study. Translational Psychiatry. https://doi.org/10.1038/s41398-018-0353-x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.